Medical Information Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Medical Information Market, By Service Provider Type

7.1.  Medical Information Market, By Service Provider Type, 2020-2030

7.1.1.    In house

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Contract outsourcing

7.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Medical Information Market, By Therapeutic Area Type

8.1.  Medical Information Market, By Therapeutic Area Type, 2020-2030

8.1.1.    Oncology

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Neurology

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Cardiology

8.1.3.1.        Market Revenue and Forecast (2016-2030)

8.1.4.    Immunology

8.1.4.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Medical Information Market, By Life Cycle Type

9.1.  Medical Information Market, By Life Cycle Type, 2020-2030

9.1.1.    Pre-clinical

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Clinical

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    Post Market Approval

9.1.3.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Medical Information Market, By Company Size Type

10.1.        Medical Information Market, By Company Size Type, 2020-2030

10.1.1.  Small

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Medium

10.1.2.1.      Market Revenue and Forecast (2016-2030)

10.1.3.  Large Scale

10.1.3.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Medical Information Market, By End-use Type

11.1.        Medical Information Market, By End-use, 2020-2030

11.1.1.  Pharmaceuticals

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  Biotechnology Companies

11.1.2.1.      Market Revenue and Forecast (2016-2030)

11.1.3.  Medical Device Manufacturers

11.1.3.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Medical Information  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

12.1.2.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.1.3.  Market Revenue and Forecast, By Life Cycle (2016-2030)

12.1.4.  Market Revenue and Forecast, By Company Size (2016-2030)

12.1.5.  Market Revenue and Forecast, By End-use (2016-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.1.6.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.1.6.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.1.6.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.1.7.  Market Revenue and Forecast, By End-use (2016-2030)

12.1.8.  Rest of North America

12.1.8.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.1.8.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.1.8.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.1.8.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.1.8.5.      Market Revenue and Forecast, By End-use (2016-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

12.2.2.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.3.  Market Revenue and Forecast, By Life Cycle (2016-2030)

12.2.4.  Market Revenue and Forecast, By Company Size (2016-2030)

12.2.5.  Market Revenue and Forecast, By End-use (2016-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.2.6.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.6.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.2.7.  Market Revenue and Forecast, By Company Size (2016-2030)

12.2.8.  Market Revenue and Forecast, By End-use (2016-2030)

12.2.9.  Germany

12.2.9.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.2.9.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.9.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.2.10.               Market Revenue and Forecast, By Company Size (2016-2030)

12.2.11.               Market Revenue and Forecast, By End-use (2016-2030)

12.2.12.               France

12.2.12.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

12.2.12.2.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.12.3.   Market Revenue and Forecast, By Life Cycle (2016-2030)

12.2.12.4.   Market Revenue and Forecast, By Company Size (2016-2030)

12.2.13.               Market Revenue and Forecast, By End-use (2016-2030)

12.2.14.               Rest of Europe

12.2.14.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

12.2.14.2.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.14.3.   Market Revenue and Forecast, By Life Cycle (2016-2030)

12.2.14.4.   Market Revenue and Forecast, By Company Size (2016-2030)

12.2.15.               Market Revenue and Forecast, By End-use (2016-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

12.3.2.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.3.  Market Revenue and Forecast, By Life Cycle (2016-2030)

12.3.4.  Market Revenue and Forecast, By Company Size (2016-2030)

12.3.5.  Market Revenue and Forecast, By End-use (2016-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.3.6.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.6.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.3.6.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.3.7.  Market Revenue and Forecast, By End-use (2016-2030)

12.3.8.  China

12.3.8.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.3.8.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.8.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.3.8.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.3.9.  Market Revenue and Forecast, By End-use (2016-2030)

12.3.10.               Japan

12.3.10.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

12.3.10.2.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.10.3.   Market Revenue and Forecast, By Life Cycle (2016-2030)

12.3.10.4.   Market Revenue and Forecast, By Company Size (2016-2030)

12.3.10.5.   Market Revenue and Forecast, By End-use (2016-2030)

12.3.11.               Rest of APAC

12.3.11.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

12.3.11.2.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.11.3.   Market Revenue and Forecast, By Life Cycle (2016-2030)

12.3.11.4.   Market Revenue and Forecast, By Company Size (2016-2030)

12.3.11.5.   Market Revenue and Forecast, By End-use (2016-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

12.4.2.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.3.  Market Revenue and Forecast, By Life Cycle (2016-2030)

12.4.4.  Market Revenue and Forecast, By Company Size (2016-2030)

12.4.5.  Market Revenue and Forecast, By End-use (2016-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.4.6.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.6.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.4.6.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.4.7.  Market Revenue and Forecast, By End-use (2016-2030)

12.4.8.  North Africa

12.4.8.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.4.8.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.8.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.4.8.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.4.9.  Market Revenue and Forecast, By End-use (2016-2030)

12.4.10.               South Africa

12.4.10.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

12.4.10.2.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.10.3.   Market Revenue and Forecast, By Life Cycle (2016-2030)

12.4.10.4.   Market Revenue and Forecast, By Company Size (2016-2030)

12.4.10.5.   Market Revenue and Forecast, By End-use (2016-2030)

12.4.11.               Rest of MEA

12.4.11.1.   Market Revenue and Forecast, By Service Provider (2016-2030)

12.4.11.2.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.11.3.   Market Revenue and Forecast, By Life Cycle (2016-2030)

12.4.11.4.   Market Revenue and Forecast, By Company Size (2016-2030)

12.4.11.5.   Market Revenue and Forecast, By End-use (2016-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, By Service Provider (2016-2030)

12.5.2.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.5.3.  Market Revenue and Forecast, By Life Cycle (2016-2030)

12.5.4.  Market Revenue and Forecast, By Company Size (2016-2030)

12.5.5.  Market Revenue and Forecast, By End-use (2016-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.5.6.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.5.6.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.5.6.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.5.7.  Market Revenue and Forecast, By End-use (2016-2030)

12.5.8.  Rest of LATAM

12.5.8.1.      Market Revenue and Forecast, By Service Provider (2016-2030)

12.5.8.2.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.5.8.3.      Market Revenue and Forecast, By Life Cycle (2016-2030)

12.5.8.4.      Market Revenue and Forecast, By Company Size (2016-2030)

12.5.8.5.      Market Revenue and Forecast, By End-use (2016-2030)

Chapter 13.  Company Profiles

13.1.              Accenture plc

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Infosys Limited

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              PAREXEL International Corporation

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              IQVIA

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              C3i Solutions

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              McKesson Corporation

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              PriemVigilance

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Propharma Group

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              Cognizant

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           PharmCentre

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

Glossary of Terms